Condition: Coronary Disease · Sponsor: Seung-Whan Lee, M.D., Ph.D.
Interested? Contact the study team ↓
This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with significant coronary artery disease undergoing percutaneous coronary intervention with drug eluting stent
This description comes directly from the study's public registry record.
Jiwon Baek, RN · 82230107267 · cvcrc22@amc.seoul.kr
Seung-Whan Lee, Investigator · 82230103170 · seungwlee@amc.seoul.kr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Men or women between the ages of 19and older * Typical chest pain or objective evidence of myocardial ischemia suitable for PCI Significant lesions with a diameter stenosis of 50-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation. * The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: * Coronary lesions resulting in the expected inability to perform FFR (ex, severe tortuosity or extreme angulation of the vessels) * Chronic total occlusion * Failed PCI of severe stenotic (diameter stenosis \> 90%) or ACS culprit lesions * Previous PCI within 6 months before the index procedure * Previous coronary artery bypass graft surgery * Cardiogenic shock or hemodynamic instability * Left ventricular dysfunction (ejection fraction \< 35%) * Life expectancy \< 1 years for any non-cardiac or cardiac causes * Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure * A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer * Patient's pregnant or breast-feeding or child-bearing potential. * A known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor) * Hypersensitivity or contraindication to DES material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated * Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study * Unwillingness or inability to comply with the procedures described in this protocol
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Hallym University Sacred Heart Hospital | Anyang, South Korea | Not Yet Recruiting |
| Bucheon Sejong Hospital | Bucheon-si, South Korea | Not Yet Recruiting |
| Inje University Busan Paik Hospital | Busan, South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, South Korea | Recruiting |
| Daegu Veterans Hospital | Daegu, South Korea | Recruiting |
| Keimyung University Dongsan Medical Center | Daegu, South Korea | Recruiting |
| Gangneung Asan Hospital | Gangneung, South Korea | Recruiting |
| Wonkwang University Hospital | Iksan, South Korea | Recruiting |
| Kwangju Christian Hospital | Kwangju, South Korea | Recruiting |
| Inje University Pusan Paik Hospital | Pusan, South Korea | Recruiting |
| Bundang CHA Hospital | Seongnam, South Korea | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.